#United States #Lexington #BIZENGRI #Cholangiocarcinoma #Zenocutuzumab-zbco

FDA Grants National Priority Voucher for BIZENGRI®

In a significant move for cancer treatment, Partner Therapeutics, Inc. (PTx) recently announced that the U.S. Food and Drug Administration (FDA) has awarded a Commissioner's National Priority Voucher (CNPV) for its innovative drug, BIZENGRI® (zenocutuzumab-zbco). This therapy is directed at adults suffering from advanced, unresectable, or metastatic cholangiocarcinoma that harbors a neuregulin 1 (NRG1) gene fusion, particularly for patients demonstrating disease progression following existing systemic therapies.

A Breakthrough for Patients with NRG1 Fusion-Positive Cholangiocarcinoma

This move is groundbreaking, especially considering the novel nature of cholangiocarcinoma, a rare and aggressive cancer affecting the bile ducts. Cholangiocarcinoma has an alarming five-year overall survival rate of less than 15%, and NRG1 fusions occur in less than 1% of diagnosed cases. Such rarity often leaves patients with limited treatment options and served as the impetus for PTx’s request for an accelerated review process.

Pritesh J. Gandhi, Chief Development Officer at Partner Therapeutics, underlined the importance of this voucher as a recognition of the unmet medical needs experienced by patients battling this ultra-rare cancer. Until now, there has been a void in approved targeted treatments for this particular type of cholangiocarcinoma, making BIZENGRI a beacon of hope. The FDA's move to grant this voucher is seen as a crucial step in addressing the urgent need for advanced treatment methods.

The Drug’s Promise and Clinical Data

The expedited review process is not merely a formality; it follows robust data gathered from the Phase 2 eNRGy trial, where BIZENGRI demonstrated promising results. This trial showcased impressive tumor responses and a favorable tolerability profile, indicating that this treatment could fill a critical gap in care for patients with NRG1 fusion-positive cholangiocarcinoma.

Stacie Lindsey, CEO of the Cholangiocarcinoma Foundation, emphasized that innovation in treatment paths and prompt diagnosis could fundamentally shift the landscape for those facing cholangiocarcinoma. The FDA’s acknowledgement of BIZENGRI reiterates the necessity for improved access to comprehensive biomarker tests — tests essential for matching patients with their most appropriate therapies early in the treatment process.

In trials, zenocutuzumab was highlighted for its clinically meaningful activity, revealing objective responses in more than a third of evaluable patients. Moreover, the median progression-free survival for these patients exceeded nine months, indicating an initial prolongation of life, allowing patients to pursue further treatment options.

What Lies Ahead?

As the FDA gears up to review BIZENGRI under its new accelerated procedure, the biotechnology landscape watches closely. The Commissioner's National Priority Voucher pilot program is designed to shorten drug review timelines significantly, potentially reducing them from a conventional period of 10 to 12 months to as little as 1 to 2 months for therapies that align well with national health priorities.

With BIZENGRI standing at the forefront as a first-in-class bispecific antibody targeting a rare and actionable oncogenic driver, the alignment with national health priorities could set a groundbreaking standard for the treatment of this challenging condition.

It’s a meticulous journey ahead as Partner Therapeutics collaborates closely with the FDA, aiming for an expeditious but thorough review, a collaboration critical to advancing treatment options for patients affected by NRG1 fusion-positive cholangiocarcinoma.

For extensive information regarding the eNRGy trial and more about zenocutuzumab-zbco, interested parties can visit the Partner Therapeutics website at www.partnertx.com.